X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs J.B.CHEMICALS - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA J.B.CHEMICALS TORRENT PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 29.4 16.0 184.1% View Chart
P/BV x 5.6 2.5 221.3% View Chart
Dividend Yield % 1.0 0.2 634.9%  

Financials

 TORRENT PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
J.B.CHEMICALS
Mar-16
TORRENT PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,768318 555.7%   
Low Rs1,186200 594.3%   
Sales per share (Unadj.) Rs346.1148.0 233.9%  
Earnings per share (Unadj.) Rs55.219.1 289.1%  
Cash flow per share (Unadj.) Rs73.323.9 306.1%  
Dividends per share (Unadj.) Rs14.000.50 2,800.0%  
Dividend yield (eoy) %0.90.2 490.7%  
Book value per share (Unadj.) Rs257.1128.9 199.4%  
Shares outstanding (eoy) m169.2284.82 199.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.31.7 244.0%   
Avg P/E ratio x26.813.6 197.4%  
P/CF ratio (eoy) x20.110.8 186.4%  
Price / Book Value ratio x5.72.0 286.2%  
Dividend payout %25.42.6 968.6%   
Avg Mkt Cap Rs m249,88721,951 1,138.4%   
No. of employees `00011.82.7 430.9%   
Total wages/salary Rs m9,9341,841 539.5%   
Avg. sales/employee Rs Th4,971.54,590.9 108.3%   
Avg. wages/employee Rs Th843.2673.4 125.2%   
Avg. net profit/employee Rs Th792.4592.1 133.8%   
INCOME DATA
Net Sales Rs m58,56912,551 466.6%  
Other income Rs m2,233542 412.3%   
Total revenues Rs m60,80213,093 464.4%   
Gross profit Rs m13,7732,055 670.3%  
Depreciation Rs m3,069412 744.2%   
Interest Rs m2,05696 2,148.0%   
Profit before tax Rs m10,8812,088 521.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,545469 329.4%   
Profit after tax Rs m9,3361,619 576.7%  
Gross profit margin %23.516.4 143.6%  
Effective tax rate %14.222.5 63.2%   
Net profit margin %15.912.9 123.6%  
BALANCE SHEET DATA
Current assets Rs m53,8417,778 692.3%   
Current liabilities Rs m31,6124,358 725.4%   
Net working cap to sales %38.027.2 139.3%  
Current ratio x1.71.8 95.4%  
Inventory Days Days9755 177.7%  
Debtors Days Days8480 104.7%  
Net fixed assets Rs m42,0795,713 736.6%   
Share capital Rs m846170 498.9%   
"Free" reserves Rs m42,65510,547 404.4%   
Net worth Rs m43,50110,937 397.7%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25015,574 650.1%  
Interest coverage x6.322.8 27.6%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.8 71.8%   
Return on assets %11.311.0 102.2%  
Return on equity %21.514.8 145.0%  
Return on capital %19.620.0 98.3%  
Exports to sales %048.7 0.0%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m20,0666,169 325.3%   
Fx outflow Rs m5,3041,285 412.7%   
Net fx Rs m14,7624,884 302.3%   
CASH FLOW
From Operations Rs m10,1271,397 725.1%  
From Investments Rs m-7,869-320 2,456.8%  
From Financial Activity Rs m-1,918-1,196 160.4%  
Net Cashflow Rs m212-102 -206.7%  

Share Holding

Indian Promoters % 71.5 55.4 129.1%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 7.0 3.4 207.1%  
FIIs % 12.6 3.9 323.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 37.0 23.8%  
Shareholders   26,511 30,437 87.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 23, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS